Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Peter LeWitt
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Chemicals & Drugs
Procedures
Anatomy
Concepts & Ideas
Living Beings
Sign-in to see full Profile
Network (preview)
24
Loeffler, David
12
Camp, Dianne
12
Juneau, PL
11
Calne, Donald
10
Chase, Thomas
6
Fahn, Stanley
6
Galloway, Matthew
6
Lang, Anthony
6
Olanow, Warren
5
Koller, William
5
Goetz, Christopher
5
Beaman, Blaine
4
Jankovic, Joseph
4
Poewe, Werner
4
Matson, Wayne
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Peter LeWitt (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: LeWitt Peter A; Jennings Danna; Lyons Kelly E; Pahwa Rajesh; Rabinowicz Adrian L; Wang James; Guarnieri Maria; Hubble Jean P; Murck Harold
Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies.
Movement disorders : official journal of the Movement Disorder Society 2009;24(9):1319-24.
-
2009: Lewitt Peter A
MAO-B inhibitor know-how: back to the pharm.
Neurology 2009;72(15):1352-7.
-
2009: LeWitt Peter A; Ondo William G; Van Lunen Brenda; Bottini Peter B
Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating "off" episodes in advanced Parkinson disease.
Clinical neuropharmacology 2009;32(2):89-93.
-
2009: LeWitt Peter A
Levodopa therapeutics for Parkinson's disease: new developments.
Parkinsonism & related disorders 2009;15 Suppl 1():S31-4.
-
2009: Camp Dianne M; Loeffler David A; Farrah Diane M; Borneman Jade N; LeWitt Peter A
Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson's disease.
Journal of neuroinflammation 2009;6():17.
-
2008: Lewitt Peter A
Levodopa for the treatment of Parkinson's disease.
The New England journal of medicine 2008;359(23):2468-76.
-
2008: Goetz Christopher G; Tilley Barbara C; Shaftman Stephanie R; Stebbins Glenn T; Fahn Stanley; Martinez-Martin Pablo; Poewe Werner; Sampaio Cristina; Stern Matthew B; Dodel Richard; Dubois Bruno; Holloway Robert; Jankovic Joseph; Kulisevsky Jaime; Lang Anthony E; Lees Andrew; Leurgans Sue; LeWitt Peter A; Nyenhuis David; Olanow C Warren; Rascol Olivier; Schrag Anette; Teresi Jeanne A; van Hilten Jacobus J; LaPelle Nancy;
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.
Movement disorders : official journal of the Movement Disorder Society 2008;23(15):2129-70.
-
2008: LeWitt Peter A; Taylor Danette C
Protection against Parkinson's disease progression: clinical experience.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2008;5(2):210-25.
-
2008: Nyholm Dag; Lewander Tommy; Johansson Anders; Lewitt Peter A; Lundqvist Christofer; Aquilonius Sten-Magnus
Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure.
Clinical neuropharmacology 2008;31(2):63-73.
-
2008: LeWitt Peter A; Guttman M; Tetrud James W; Tuite Paul J; Mori Akihisa; Chaikin Philip; Sussman Neil M;
Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
Annals of neurology 2008;63(3):295-302.
-
2007: Haq Ihtsham Ul; Lewitt Peter A; Fernandez Hubert H
Apomorphine therapy in Parkinson's disease: a review.
Expert opinion on pharmacotherapy 2007;8(16):2799-809.
-
2007: LeWitt Peter A
A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition.
Clinical neuropharmacology 2007;30(5):305-7.
-
2007: LeWitt Peter A; Boroojerdi Babak; MacMahon Douglas; Patton James; Jankovic Joseph
Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.
Clinical neuropharmacology 2007;30(5):256-65.
-
2007: LeWitt Peter A; Lyons Kelly E; Pahwa Rajesh;
Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study.
Neurology 2007;68(16):1262-7.
-
2007: Goetz Christopher G; Fahn Stanley; Martinez-Martin Pablo; Poewe Werner; Sampaio Cristina; Stebbins Glenn T; Stern Matthew B; Tilley Barbara C; Dodel Richard; Dubois Bruno; Holloway Robert; Jankovic Joseph; Kulisevsky Jaime; Lang Anthony E; Lees Andrew; Leurgans Sue; LeWitt Peter A; Nyenhuis David; Olanow C Warren; Rascol Olivier; Schrag Anette; Teresi Jeanne A; Van Hilten Jacobus J; LaPelle Nancy
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan.
Movement disorders : official journal of the Movement Disorder Society 2007;22(1):41-7.
-
2006: Olanow C Warren; Schapira Anthony H V; LeWitt Peter A; Kieburtz Karl; Sauer Dirk; Olivieri Gianfranco; Pohlmann Harald; Hubble Jean
TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial.
Lancet neurology 2006;5(12):1013-20.
-
2006: LeWitt P A
Neuroprotection for Parkinson's disease.
Journal of neural transmission. Supplementum 2006;(71):113-22.
-
2005: Lu Lin; Camp Dianne M; Loeffler David A; LeWitt Peter A
Lack of evidence for Nocardia asteroides in brain specimens from Lewy body-containing disorders.
Microbial pathogenesis 2005;39(5-6):205-11.
-
2005: Stacy Mark; Bowron Annette; Guttman Mark; Hauser Robert; Hughes Kim; Larsen Jan Petter; LeWitt Peter; Oertel Wolfgang; Quinn Niall; Sethi Kapil; Stocchi Fabrizio
Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.
Movement disorders : official journal of the Movement Disorder Society 2005;20(6):726-33.
-
2005: LeWitt Peter
Rotigotine: a viewpoint by Peter LeWitt.
CNS drugs 2005;19(11):983-4.
-
2004: LeWitt Peter A
Clinical trials of neuroprotection for Parkinson's disease.
Neurology 2004;63(7 Suppl 2):S23-31.
-
2004: Olanow C Warren; Agid Yves; Mizuno Yoshi; Albanese Alberto; Bonuccelli Ubaldo; Damier Philip; De Yebenes Justo; Gershanik Oscar; Guttman Mark; Grandas F; Hallett Mark; Hornykiewicz Ole; Jenner Peter; Katzenschlager R; Langston William J; LeWitt Peter; Melamed Eldad; Mena M A; Michel P P; Mytilineou Catherine; Obeso Jose A; Poewe Werner; Quinn Niall; Raisman-Vozari R; Rajput Ali H; Rascol Olivier; Sampaio Christina; Stocchi Fabrizio
Levodopa in the treatment of Parkinson's disease: current controversies.
Movement disorders : official journal of the Movement Disorder Society 2004;19(9):997-1005.
-
2004: Loeffler David A; Camp Dianne M; Schonberger Michael B; Singer Daniel J; LeWitt Peter A
Early complement activation increases in the brain in some aged normal subjects.
Neurobiology of aging 2004;25(8):1001-7.
-
2004: Loeffler David A; Camp Dianne M; Qu Shirley; Beaman Blaine L; LeWitt Peter A
Characterization of dopamine-depleting activity of Nocardia asteroides strain GUH-2 culture filtrate on PC12 cells.
Microbial pathogenesis 2004;37(2):73-85.
-
2004: Stern Matthew B; Marek Kenneth L; Friedman Joseph; Hauser Robert A; LeWitt Peter A; Tarsy Daniel; Olanow C Warren
Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
Movement disorders : official journal of the Movement Disorder Society 2004;19(8):916-23.
-
2004: Holloway Robert G; Shoulson Ira; Fahn Stanley; Kieburtz Karl; Lang Anthony; Marek Kenneth; McDermott Michael; Seibyl John; Weiner William; Musch Bruno; Kamp Cornelia; Welsh Mickie; Shinaman Aileen; Pahwa Rajesh; Barclay Lynn; Hubble Jean; LeWitt Peter; Miyasaki Janis; Suchowersky Oksana; Stacy Mark; Russell David S; Ford Blair; Hammerstad John; Riley David; Standaert David; Wooten Frederick; Factor Stewart; Jankovic Joseph; Atassi Farah; Kurlan Roger; Panisset Michel; Rajput Ali; Rodnitzky Robert; Shults Cliff; Petsinger Giselle; Waters Cheryl; Pfeiffer Ronald; Biglan Kevin; Borchert Leona; Montgomery Amy; Sutherland Laura; Weeks Carolyn; DeAngelis Maryan; Sime Elspeth; Wood Susan; Pantella Carol; Harrigan Mary; Fussell Barbara; Dillon Sandra; Alexander-Brown Barbara; Rainey Pamela; Tennis Marsha; Rost-Ruffner Elke; Brown Diane; Evans Sharon; Berry Debra; Hall Jean; Shirley Theresa; Dobson Judith; Fontaine Deborah; Pfeiffer Brenda; Brocht Alicia; Bennett Susan; Daigneault Susan; Hodgeman Karen; O'Connell Carolynn; Ross Tori; Richard Karen; Watts Arthur;
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Archives of neurology 2004;61(7):1044-53.
-
2004: LeWitt Peter A
Subcutaneously administered apomorphine: pharmacokinetics and metabolism.
Neurology 2004;62(6 Suppl 4):S8-11.
-
2004: LeWitt Peter A; Nyholm Dag
New developments in levodopa therapy.
Neurology 2004;62(1 Suppl 1):S9-16.
-
2004: Loeffler David A; Camp Dianne M; Nichols Lihua Qu; Maksaereekul Saipiroon; Beaman Blaine L; LeWitt Peter A
Comparison of PCR and culture for detection of Nocardia asteroides in brain specimens from experimentally infected BALB/c mice.
Microbiological research 2004;159(3):277-83.
-
2003: Chapman Gail; Beaman Blaine L; Loeffler David A; Camp Dianne M; Domino Edward F; Dickson Dennis W; Ellis William G; Chen Ibsen; Bachus Susan E; LeWitt Peter A
In situ hybridization for detection of nocardial 16S rRNA: reactivity within intracellular inclusions in experimentally infected cynomolgus monkeys--and in Lewy body-containing human brain specimens.
Experimental neurology 2003;184(2):715-25.
-
2003: Goetz Christopher G; LeWitt Peter A; Weidenman Meredith
Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program.
Movement disorders : official journal of the Movement Disorder Society 2003;18(12):1455-8.
-
2003: Camp Dianne M; Loeffler David A; Razoky Bnan A; Tam Stanley; Beaman Blaine L; LeWitt Peter A
Nocardia asteroides culture filtrates cause dopamine depletion and cytotoxicity in PC12 cells.
Neurochemical research 2003;28(9):1359-67.
-
2003: Lorenzl S; Albers D S; LeWitt P A; Chirichigno J W; Hilgenberg S L; Cudkowicz M E; Beal M F
Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases.
Journal of the neurological sciences 2003;207(1-2):71-6.
-
2002: Shoulson Ira; Oakes David; Fahn Stanley; Lang Anthony; Langston J William; LeWitt Peter; Olanow C Warren; Penney John B; Tanner Caroline; Kieburtz Karl; Rudolph Alice;
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
Annals of neurology 2002;51(5):604-12.
-
2001: Dewey R B; Hutton J T; LeWitt P A; Factor S A
A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.
Archives of neurology 2001;58(9):1385-92.
-
2001: Loeffler D A; Sima A A; LeWitt P A
Ceruloplasmin immunoreactivity in neurodegenerative disorders.
Free radical research 2001;35(2):111-8.
-
2001: Hutton J T; Metman L V; Chase T N; Juncos J L; Koller W C; Pahwa R; LeWitt P A; Samii A; Tsui J K; Calne D B; Waters C H; Calabrese V P; Bennett J P; Barrett R; Morris J L
Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study.
Movement disorders : official journal of the Movement Disorder Society 2001;16(3):459-63.
-
2001: Heikkinen H; Nutt J G; LeWitt P A; Koller W C; Gordin A
The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
Clinical neuropharmacology 2001;24(3):150-7.
-
2001: Shoulson I; Penney J; McDermott M; Schwid S; Kayson E; Chase T; Fahn S; Greenamyre J T; Lang A; Siderowf A; Pearson N; Harrison M; Rost E; Colcher A; Lloyd M; Matthews M; Pahwa R; McGuire D; Lew M F; Schuman S; Marek K; Broshjeit S; Factor S; Brown D; Feigin A; Mazurkiewicz J; Ford B; Jennings D; Dilllon S; Comella C; Blasucci L; Janko K; Shulman L; Wiener W; Bateman-Rodriguez D; Carrion A; Suchowersky O; Lafontaine A L; Pantella C; Siemers E; Belden J; Davies R; Lannon M; Grimes D; Gray P; Martin W; Kennedy L; Adler C; Newman S; Hammerstad J; Stone C; Lewitt P; Bardram K; Mistura K; Miyasaki J; Johnston L; Cha J H; Tennis M; Panniset M; Hall J; Tetrud J; Friedlander J; Hauser R; Gauger L; Rodnitzky R; Deleo A; Dobson J; Seeberger L; Dingmann C; Tarsy D; Ryan P; Elmer L; Ruzicka D; Stacy M; Brewer M; Locke B; Baker D; Casaceli C; Day D; Florack M; Hodgeman K; Laroia N; Nobel R; Orme C; Rexo L; Rothenburgh K; Sulimowicz K; Watts A; Wratni E; Tariot P; Cox C; Leventhal C; Alderfer V; Craun A M; Frey J; McCree L; McDermott J; Cooper J; Holdich T; Read B;
A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease.
Neurology 2001;56(4):455-62.
-
2000: Loeffler D A; Camp D M; Juneau P L; Harel E; LeWitt P A
Purine-induced alterations of dopamine metabolism in rat pheochromocytoma PC12 cells.
Brain research bulletin 2000;52(6):553-8.
-
2000: Hyland K; Beaman B L; LeWitt P A; DeMaggio A J
Monoamine changes in the brain of BALB/c mice following sub-lethal infection with Nocardia asteroides (GUH-2).
Neurochemical research 2000;25(4):443-8.
-
2000: Jorga K M; Davis T L; Kurth M C; Saint-Hilaire M H; LeWitt P A; Fotteler B; Zürcher G; Rabbia M
Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism.
Clinical neuropharmacology 2000;23(2):98-105.
-
2000: Camp D M; Loeffler D A; LeWitt P A
L-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with a unilateral 6-hydroxydopamine lesion.
Journal of neurochemistry 2000;74(3):1229-40.
-
2000: Damiano A M; McGrath M M; Willian M K; Snyder C F; LeWitt P A; Reyes P F; Richter R R; Means E D
Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2000;9(1):87-100.
-
2000: LeWitt P A
New drugs for the treatment of Parkinson's disease.
Pharmacotherapy 2000;20(1 Pt 2):26S-32S.
-
2000: LeWitt P A
The challenge of managing mild Parkinson's disease.
Pharmacotherapy 2000;20(1 Pt 2):2S-7S.
-
1999: Agid Y; Ahlskog E; Albanese A; Calne D; Chase T; De Yebenes J; Factor S; Fahn S; Gershanik O; Goetz C; Koller W; Kurth M; Lang A; Lees A; Lewitt P; Marsden D; Melamed E; Michel P P; Mizuno Y; Obeso J; Oertel W; Olanow W; Poewe W; Pollak P; Tolosa E
Levodopa in the treatment of Parkinson's disease: a consensus meeting.
Movement disorders : official journal of the Movement Disorder Society 1999;14(6):911-3.
-
1999: Loeffler D A; Linder M C; Zamany M; Harel E; Paul M A; Baumann H; LeWitt P A
Measurement of acute phase proteins in the rat brain: contribution of vascular contents.
Neurochemical research 1999;24(10):1313-7.
-
1999: LeWitt P A
Penicillamine as a controversial treatment for Wilson's disease.
Movement disorders : official journal of the Movement Disorder Society 1999;14(4):555-6.
-
1999: LeWitt P A
Micrographia after thalamo-mesencephalic infarction.
Neurology 1999;52(9):1921; author reply 1921-2.
-
1999: Klein C; Page C E; LeWitt P; Gordon M F; de Leon D; Awaad Y; Breakefield X O; Brin M F; Ozelius L J
Genetic analysis of three patients with an 18p- syndrome and dystonia.
Neurology 1999;52(3):649-51.
-
1999: LeWitt P A; Albanese A
New delivery systems for antiparkinsonian drugs.
Advances in neurology 1999;80():549-54.
-
1998: Loeffler D A; LeWitt P A; Juneau P L; Camp D M; Arnold L A; Hyland K
Time-dependent effects of levodopa on regional brain dopamine metabolism and lipid peroxidation.
Brain research bulletin 1998;47(6):663-7.
-
1998: Loeffler D A; LeWitt P A; Juneau P L; Camp D M; DeMaggio A J; Havaich M K; Milbury P E; Matson W R
Influence of repeated levodopa administration on rabbit striatal serotonin metabolism, and comparison between striatal and CSF alterations.
Neurochemical research 1998;23(12):1521-5.
-
1998: LeWitt P A
Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1998;13(4):731-4.
-
1998: Trosch R M; Friedman J H; Lannon M C; Pahwa R; Smith D; Seeberger L C; O'Brien C F; LeWitt P A; Koller W C
Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience.
Movement disorders : official journal of the Movement Disorder Society 1998;13(3):377-82.
-
1998: Waters C H; Kurth M; Bailey P; Shulman L M; LeWitt P; Dorflinger E; Deptula D; Pedder S
Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group.
Neurology 1998;50(5 Suppl 5):S39-45.
-
1998: Loeffler D A; LeWitt P A; Juneau P L; Camp D M; DeMaggio A J; Milbury P; Matson W R; Rathbone M P
Altered guanosine and guanine concentrations in rabbit striatum following increased dopamine turnover.
Brain research bulletin 1998;45(3):297-9.
-
1997: LeWitt P A; Trosch R M
Idiosyncratic adverse reactions to intramuscular botulinum toxin type A injection.
Movement disorders : official journal of the Movement Disorder Society 1997;12(6):1064-7.
-
1997: Loeffler D A; Brickman C M; Juneau P L; Perry M F; Pomara N; Lewitt P A
Cerebrospinal fluid C3a increases with age, but does not increase further in Alzheimer's disease.
Neurobiology of aging 1997;18(5):555-7.
-
1997: Waters C H; Kurth M; Bailey P; Shulman L M; LeWitt P; Dorflinger E; Deptula D; Pedder S
Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group.
Neurology 1997;49(3):665-71.
-
1997: LeWitt P A
New options for treatment of Parkinson's disease.
Baillière's clinical neurology 1997;6(1):109-23.
-
1997: LeWitt P; Oakes D; Cui L
The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
Movement disorders : official journal of the Movement Disorder Society 1997;12(2):183-9.
-
1997: Loeffler D A; Juneau P L; Nguyen H U; Najman D; Pomara N; LeWitt P A
Immunocytochemical detection of anti-hippocampal antibodies in Alzheimer's disease and normal cerebrospinal fluid.
Neurochemical research 1997;22(2):209-14.
-
1997: Kurth M C; Adler C H; Hilaire M S; Singer C; Waters C; LeWitt P; Chernik D A; Dorflinger E E; Yoo K
Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I.
Neurology 1997;48(1):81-7.
-
1996: Loeffler D A; LeWitt P A; Juneau P L; Sima A A; Nguyen H U; DeMaggio A J; Brickman C M; Brewer G J; Dick R D; Troyer M D; Kanaley L
Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders.
Brain research 1996;738(2):265-74.
-
1995: Connor J R; Snyder B S; Arosio P; Loeffler D A; LeWitt P
A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains.
Journal of neurochemistry 1995;65(2):717-24.
-
1995: Loeffler D A; Connor J R; Juneau P L; Snyder B S; Kanaley L; DeMaggio A J; Nguyen H; Brickman C M; LeWitt P A
Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions.
Journal of neurochemistry 1995;65(2):710-24.
-
1995: Loeffler D A; LeWitt P A; DeMaggio A J; Juneau P L; Milbury P E; Matson W R
Markers of dopamine depletion and compensatory response in striatum and cerebrospinal fluid.
Journal of neural transmission. Parkinson's disease and dementia section 1995;9(1):45-53.
-
1994: Loeffler D A; Demaggio A J; Juneau P L; Havaich M; Lewitt P A
Levodopa administration to normal rats: influence on striatal oxidized glutathione concentration.
Annals of the New York Academy of Sciences 1994;738():421-6.
-
1994: LeWitt P A; Bharucha A; Chitrit I; Takis C; Patil S; Schork M A; Pichurko B
Perceived exertion and muscle efficiency in Parkinson's disease: L-DOPA effects.
Clinical neuropharmacology 1994;17(5):454-9.
-
1994: Loeffler D A; DeMaggio A J; Juneau P L; Havaich M K; LeWitt P A
Effects of enhanced striatal dopamine turnover in vivo on glutathione oxidation.
Clinical neuropharmacology 1994;17(4):370-9.
-
1994: Loeffler D A; DeMaggio A J; Juneau P L; Brickman C M; Mashour G A; Finkelman J H; Pomara N; LeWitt P A
Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease.
Alzheimer disease and associated disorders 1994;8(3):190-7.
-
1994: LeWitt P A
Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment.
Journal of neural transmission. Supplementum 1994;43():171-81.
-
1993: LeWitt P A
Levodopa therapeutics: new treatment strategies.
Neurology 1993;43(12 Suppl 6):S31-7.
-
1993: LeWitt P A; Segel S A; Mistura K L; Schork M A
Symptomatic anti-parkinsonian effects of monoamine oxidase-B inhibition: comparison of selegiline and lazabemide.
Clinical neuropharmacology 1993;16(4):332-7.
-
1993: LeWitt P A; Walters A; Hening W; McHale D
Persistent movement disorders induced by buspirone.
Movement disorders : official journal of the Movement Disorder Society 1993;8(3):331-4.
-
1993: LeWitt P A
Assessment of the dopaminergic lesion in Parkinson's disease by CSF markers.
Advances in neurology 1993;60():544-7.
-
1993: LeWitt P A
Neuroprotection by anti-oxidant strategies in Parkinson's disease.
European neurology 1993;33 Suppl 1():24-30.
-
1992: LeWitt P A; Galloway M P; Matson W; Milbury P; McDermott M; Srivastava D K; Oakes D
Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group.
Neurology 1992;42(11):2111-7.
-
1992: Dysken M W; Mendels J; LeWitt P; Reisberg B; Pomara N; Wood J; Skare S; Fakouhi J D; Herting R L
Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type.
Journal of the American Geriatrics Society 1992;40(5):503-6.
-
1992: LeWitt P A
Treatment strategies for extension of levodopa effect.
Neurologic clinics 1992;10(2):511-26.
-
1992: Loeffler D A; Brickman C M; LeWitt P A; Bannon M J; KuKuruga M A; Cassin B; Kapatos G
Non-specific binding of normal human IgG, including F(ab')2 and Fc fragments, to embryonic rat brain neurons and human cortex synaptosomes.
Journal of neuroimmunology 1992;38(1-2):45-52.
-
1992: Pomara N; Singh R; Deptula D; Chou J C; Schwartz M B; LeWitt P A
Glutamate and other CSF amino acids in Alzheimer's disease.
The American journal of psychiatry 1992;149(2):251-4.
-
1992: LeWitt P A
Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.
Neurology 1992;42(1 Suppl 1):29-32; discussion 57-60.
-
1992: LeWitt P A
Therapeutics of Tourette syndrome. New medication approaches.
Advances in neurology 1992;58():263-70.
-
1992: Pomara N; Stanley M; LeWitt P A; Galloway M; Singh R; Deptula D
Increased CSF HVA response to arecoline challenge in Alzheimer's disease.
Journal of neural transmission. General section 1992;90(1):53-65.
-
1991: Koller W C; Block G A; Ahlskog J E; Ahrens S; Cedarbaum J M; Cyhan G; Goetz C G; LeWitt P A; Liss C; McLean L
Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study.
Clinical neuropharmacology 1991;14(4):322-9.
-
1991: Wolf M E; LeWitt P A; Bannon M J; Dragovic L J; Kapatos G
Effect of aging on tyrosine hydroxylase protein content and the relative number of dopamine nerve terminals in human caudate.
Journal of neurochemistry 1991;56(4):1191-200.
-
1991: Prell G D; Khandelwal J K; Burns R S; LeWitt P A; Green J P
Influence of age and gender on the levels of histamine metabolites and pros-methylimidazoleacetic acid in human cerebrospinal fluid.
Archives of gerontology and geriatrics 1991;12(1):1-12.
-
1991: LeWitt P A
Deprenyl's effect at slowing progression of parkinsonian disability: the DATATOP study. The Parkinson Study Group.
Acta neurologica Scandinavica. Supplementum 1991;136():79-86.
-
1990: Kelland M D; Freeman A S; LeWitt P A; Chiodo L A
Effects of (+)-4-propyl-9-hydroxynaphthoxazine on midbrain dopamine neurons: an electrophysiological study.
The Journal of pharmacology and experimental therapeutics 1990;255(1):276-84.
-
1990: Prell G D; Khandelwal J K; Burns R S; LeWitt P A; Green J P
Influence of age and gender on the levels of histamine metabolites and pros-methylimidazoleacetic acid in human cerebrospinal fluid.
Archives of gerontology and geriatrics 1990;11(1):85-95.
-
1990: Nelson M V; Berchou R C; Kareti D; LeWitt P A
Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine.
Clinical pharmacology and therapeutics 1990;47(6):694-7.
-
1990: LeWitt P A
Orthostatic tremor: the phenomenon of 'paradoxical clonus'.
Archives of neurology 1990;47(5):501-2.
-
1990: Nelson M V; Berchou R C; LeWitt P A; Kareti D; Galloway M P
Pharmacodynamic modeling of concentration-effect relationships after controlled-release carbidopa/levodopa (Sinemet CR4) in Parkinson's disease.
Neurology 1990;40(1):70-4.
-
1989: LeWitt P A; Nelson M V; Berchou R C; Galloway M P; Kesaree N; Kareti D; Schlick P
Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
Neurology 1989;39(11 Suppl 2):45-53; discussion 59.
-
1989: Pomara N; Singh R R; Deptula D; LeWitt P A; Bissette G; Stanley M; Nemeroff C B
CSF corticotropin-releasing factor (CRF) in Alzheimer's disease: its relationship to severity of dementia and monoamine metabolites.
Biological psychiatry 1989;26(5):500-4.
-
1989: Pomara N; Deptula D; Galloway M P; LeWitt P A; Stanley M
CSF GABA in caregiver spouses of Alzheimer patients.
The American journal of psychiatry 1989;146(6):787-8.
-
1989: Nelson M V; Berchou R C; Lewitt P A; Kareti D; Kesaree N; Schlick P; Galloway M P
Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet.
Clinical neuropharmacology 1989;12(2):91-7.
-
1989: Prell G D; Khandelwal J K; LeWitt P A; Green J P
Rostral-caudal concentration gradients of histamine metabolites in human cerebrospinal fluid.
Agents and actions 1989;26(3-4):267-72.
-
1988: Prell G D; Khandelwal J K; Burns R S; LeWitt P A; Green J P
Elevated levels of histamine metabolites in cerebrospinal fluid of aging, healthy humans.
Comprehensive gerontology. Section A, Clinical and laboratory sciences 1988;2(3):114-9.
-
1988: Syrigou-Papavasiliou A; Lycaki H; LeWitt P A; Verma N P; Spivak D; Chayasirisobhon S
Dose-response effects of chronic methylphenidate administration on late event-related potentials in attention deficit disorder.
Clinical EEG (electroencephalography) 1988;19(3):129-33.
-
1988: Sanes J N; LeWitt P A; Mauritz K H
Visual and mechanical control of postural and kinetic tremor in cerebellar system disorders.
Journal of neurology, neurosurgery, and psychiatry 1988;51(7):934-43.
-
1988: LeWitt P A; Martin S D
Dystonia and hypokinesis with putaminal necrosis after methanol intoxication.
Clinical neuropharmacology 1988;11(2):161-7.
-
1988: Spicer K B; Roberts R J; LeWitt P A
Neuropsychological performance in lateralized parkinsonism.
Archives of neurology 1988;45(4):429-32.
-
1988: Syrigou-Papavasiliou A; Verma N P; LeWitt P A
Sensory evoked responses in Tourette syndrome.
Clinical EEG (electroencephalography) 1988;19(2):108-10.
-
1988: LeWitt P
Hyperhidrosis and hypothermia responsive to oxybutynin.
Neurology 1988;38(3):506-7.
-
1988: LeWitt P A
Neuropharmacological intervention with motor system aging.
Annals of the New York Academy of Sciences 1988;515():376-82.
-
1988: LeWitt P A; Miller L P; Levine R A; Lovenberg W; Newman R P; Papavasiliou A; Rayes A; Eldridge R; Burns R S
Pterin abnormalities in dystonia: a metabolic marker with therapeutic implications.
Advances in neurology 1988;50():193-201.
-
1987: Townsend L E; Gilroy J; LeWitt P; Wolfe D E; Pomara N; Weintraub J; Reitz D
Comparison of methods for analysis of CSF proteins in patients with Alzheimer's disease.
Neurochemical pathology 1987;6(3):213-29.
-
1987: Moore N C; Meyendorff E; Yeragani V; LeWitt P A; Gershon S
Tiaspirone in schizophrenia.
Journal of clinical psychopharmacology 1987;7(2):98-101.
-
1986: Verma N P; Syrigou-Papavasiliou A; LeWitt P A
Electroencephalographic findings in unmedicated, neurologically and intellectually intact Tourette syndrome patients.
Electroencephalography and clinical neurophysiology 1986;64(1):12-20.
-
1986: LeWitt P A; Miller L P; Levine R A; Lovenberg W; Newman R P; Papavasiliou A; Rayes A; Eldridge R; Burns R S
Tetrahydrobiopterin in dystonia: identification of abnormal metabolism and therapeutic trials.
Neurology 1986;36(6):760-4.
-
1986: Teräväinen H; Huttunen J; Lewitt P
Ineffective treatment of essential tremor with an alcohol, methylpentynol.
Journal of neurology, neurosurgery, and psychiatry 1986;49(2):198-9.
-
1986: LeWitt P A; Burns R S; Newman R P
Dystonia in untreated parkinsonism.
Clinical neuropharmacology 1986;9(3):293-7.
-
1986: Cullis P A; Townsend L; LeWitt P; Pomara N; Reitz D
Electrophoresis and immunoblot of cerebrospinal fluid proteins in spasmodic torticollis.
Movement disorders : official journal of the Movement Disorder Society 1986;1(3):179-86.
-
1986: LeWitt P A
New perspectives in the treatment of Parkinson's disease.
Clinical neuropharmacology 1986;9 Suppl 1():S37-54.
-
1986: Ludwig C L; Weinberger D R; Bruno G; Gillespie M; Bakker K; LeWitt P A; Chase T N
Buspirone, Parkinson's disease, and the locus ceruleus.
Clinical neuropharmacology 1986;9(4):373-8.
-
1985: LeWitt P A; Forno L S
Peripheral neuropathy following amitriptyline overdose.
Muscle & nerve 1985;8(8):723-4.
-
1985: LeWitt P A; Oxenkrug G F; McIntyre I M; McCauley R M
Peripheral carbidopa affects striatal monoamine oxidase activity.
Neurology 1985;35(8):1258-9.
-
1985: Burns R S; LeWitt P A; Ebert M H; Pakkenberg H; Kopin I J
The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
The New England journal of medicine 1985;312(22):1418-21.
-
1985: Tamminga C A; LeWitt P A; Chase T N
Cholecystokinin and neurotensin gradients in human CSF.
Archives of neurology 1985;42(4):354-5.
-
1985: Newman R P; LeWitt P A; Jaffe M; Calne D B; Larsen T A
Motor function in the normal aging population: treatment with levodopa.
Neurology 1985;35(4):571-3.
-
1985: Hurst J H; LeWitt P A; Burns R S; Foster N L; Lovenberg W
CSF dopamine-beta-hydroxylase activity in Parkinson's disease.
Neurology 1985;35(4):565-8.
-
1985: Newman R P; LeWitt P A; Shults C; Bruno G; Foster N L; Chase T N; Calne D B
Dystonia: treatment with bromocriptine.
Clinical neuropharmacology 1985;8(4):328-33.
-
1985: Newman R P; Tamminga C A; Chase T N; LeWitt P A
EMD 23,448: effects of a putative dopamine autoreceptor agonist in chorea.
Journal of neural transmission 1985;61(1-2):125-9.
-
1984: Foster N L; Newman R P; LeWitt P A; Gillespie M M; Larsen T A; Chase T N
Peripheral beta-adrenergic blockade treatment of parkinsonian tremor.
Annals of neurology 1984;16(4):505-8.
-
1984: Foster N L; Newman R P; LeWitt P A; Gillespie M M; Chase T N
Treatment of resting tremor by beta-adrenergic blockade.
American heart journal 1984;108(4 Pt 2):1173-7.
-
1984: Larsen T A; Newman R; LeWitt P; Calne D B
Severity of Parkinson's disease and the dosage of bromocriptine.
Neurology 1984;34(6):795-7.
-
1984: Karson C N; Burns R S; LeWitt P A; Foster N L; Newman R P
Blink rates and disorders of movement.
Neurology 1984;34(5):677-8.
-
1984: Weingartner H; Burns S; Diebel R; LeWitt P A
Cognitive impairments in Parkinson's disease: distinguishing between effort-demanding and automatic cognitive processes.
Psychiatry research 1984;11(3):223-35.
-
1984: LeWitt P A
Neurosarcoidosis and headache.
Southern medical journal 1984;77(2):272-3.
-
1984: LeWitt P A; Miller L P; Newman R P; Burns R S; Insel T; Levine R A; Lovenberg W; Calne D B
Tyrosine hydroxylase cofactor (tetrahydrobiopterin) in parkinsonism.
Advances in neurology 1984;40():459-62.
-
1983: Lewitt P A
Micrographia as a focal sign of neurological disease.
Journal of neurology, neurosurgery, and psychiatry 1983;46(12):1152-3.
-
1983: Karson C N; Jeste D V; LeWitt P A; Wyatt R J
A comparison of two iatrogenic dyskinesias.
The American journal of psychiatry 1983;140(11):1504-6.
-
1983: Papadopoulos N M; LeWitt P A; Newman R P; Raphaelson M I; Chase T N
A unique protein in normal human cerebrospinal fluid.
Clinical chemistry 1983;29(10):1842-4.
-
1983: LeWitt P A; Newman R P; Greenberg H S; Rocher L L; Calne D B; Ehrenkranz J R
Episodic hyperhidrosis, hypothermia, and agenesis of corpus callosum.
Neurology 1983;33(9):1122-9.
-
1983: LeWitt P A; Ward C D; Larsen T A; Raphaelson M I; Newman R P; Foster N; Dambrosia J M; Calne D B
Comparison of pergolide and bromocriptine therapy in parkinsonism.
Neurology 1983;33(8):1009-14.
-
1983: LeWitt P A; Newman R P; Miller L P; Lovenberg W; Eldridge R
Treatment of dystonia with tetrahydrobiopterin.
The New England journal of medicine 1983;308(3):157-8.
-
1983: LeWitt P A; Forno L S; Brant-Zawadzki M
Neoplastic angioendotheliosis: a case with spontaneous regression and radiographic appearance of cerebral arteritis.
Neurology 1983;33(1):39-44.
-
1983: LeWitt P A; Burns R S; Calne D B
Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies.
Advances in neurology 1983;37():131-40.
-
1982: Karson C N; LeWitt P A; Calne D B; Wyatt R J
Blink rates in parkinsonism.
Annals of neurology 1982;12(6):580-3.
-
1982: LeWitt P A; Barton N W; Posner J B
Hiccup with dexamethasone therapy.
Annals of neurology 1982;12(4):405-6.
-
1982: LeWitt P A; Ehrenkranz J R
TRH and spinocerebellar degeneration.
Lancet 1982;2(8305):981.
-
1982: LeWitt P A; Gopinathan G; Ward C D; Sanes J N; Dambrosia J M; Durso R; Calne D B
Lisuride versus bromocriptine treatment in Parkinson disease: a double-blind study.
Neurology 1982;32(1):69-72.
-
1981: LeWitt P A
Transient ophthalmoparesis with doxepin overdosage.
Annals of neurology 1981;9(6):618.
-
1980: Karam J H; Lewitt P A; Young C W; Nowlain R E; Frankel B J; Fujiya H; Freedman Z R; Grodsky G M
Insulinopenic diabetes after rodenticide (Vacor) ingestion: a unique model of acquired diabetes in man.
Diabetes 1980;29(12):971-8.
-
1980: LeWitt P
PNU intoxication.
American journal of diseases of children (1960) 1980;134(12):1178.
-
1980: LeWitt P A
The neurotoxicity of the rat poison vacor. A clinical study of 12 cases.
The New England journal of medicine 1980;302(2):73-7.
-
1978: LeWitt P
"Paradoxical clonus": rhythmic contractions evoked in passively shortened muscle.
Annals of neurology 1978;4(5):481-2.
-
1978: Karam J H; Prosser P R; Lewitt P A
Islet-cell surface antibodies in a patient with diabetes mellitus after rodenticide ingestion.
The New England journal of medicine 1978;299(21):1191.
-
1978: Angel R W; Lewitt P A
Unloading and shortening reactions in Parkinson's disease.
Journal of neurology, neurosurgery, and psychiatry 1978;41(10):919-23.
-
1975: LeWitt P
The class of 1975: a differential diagnosis.
R.I. medical journal 1975;58(5):207-14.
Sign-in to see more
